Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Mar 30;6:23893. doi: 10.1038/srep23893

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients

Xiaobin Gu 1,*, Shaoqian Sun 1,*, Xian-Shu Gao 1,a, Wei Xiong 2, Shangbin Qin 1, Xin Qi 1, Mingwei Ma 1, Xiaoying Li 1, Dong Zhou 1, Wen Wang 1, Hao Yu 1
PMCID: PMC4812293  PMID: 27025911

Abstract

This study was designed to explore the association between elevated platelet to lymphocyte ratio (PLR) and prognosis of patients with non-small cell lung cancer (NSCLC) by meta-analysis. A total of 11 studies with 3,430 subjects were included and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. The data showed that elevated PLR predicted poor overall survival (OS) (HR = 1.42; 95% CI: 1.25–1.61, p < 0.001; I2 = 63.6, Ph = 0.002) and poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.19; 95% CI: 1.02–1.4, p = 0.027; I2 = 46.8, Ph = 0.111). Subgroup analysis showed elevated PLR did not predict poor OS in patients included in large sample studies (HR = 1.44; 95% CI: 0.94–2.21, p = 0.098) whereas petients with Caucasian ethnicity (HR = 1.59; 95% CI: 1.27–1.98, p < 0.001) and PLR cut-off value >180 (HR = 1.61; 95% CI: 1.3–1.99, p < 0.001) had enhanced prognostic efficiency for OS. Subgroup analysis also demonstrated that high PLR did not predict poor DFS/PFS in Asian patients. In conclusion, our meta-analysis suggested that elevated PLR was associated with poor OS and DFS/PFS in NSCLC. In addition, high PLR especially predicted poor OS in Caucasians but had no association with poor DFS/PFS in Asians.

Lung cancer is one of the most commonly diagnosed cancer forms and the leading cause of cancer related mortality in both developed and developing countries1. Lung cancer mainly consists of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for more than 80% of all lung cancer cases. The major treatment methods for NSCLC are surgery, chemotherapy and radiotherapy, in addition, targeted therapies on the specific gene mutations (e.g. EGFR, ALK etc.) have shown encouraging effects2,3. In spite of these, the 5-year survival rate of NSCLC is only 16.6% because about two-thirds of NSCLC patients are at locally advanced or metastatic stage when diagnosed4,5. The poor survival of NSCLC is partly due to absence of efficacious biomarkers. Traditional prognostic biomarkers such as ECOG PS, weight loss and pleural effusion provided limited implication for treatment and several emerging biomarkers including EGFR mutations and ALK gene rearrangements only provided useful information for clinical management for a small proportion of patients6,7. The identification of novel prognostic factors could help stratify risk patients and guide therapy modalities selection.

Accumulated evidence show that host’s inflammatory response plays an important role in cancer progression and prognosis8,9. In recent years, a variety of inflammatory indices such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP) and modified Glasgow prognostic score (mGPS) have attracted extensive attention for their prognostic efficiency in cancer patients10,11. Notably, as an easily measured blood-based parameter, PLR was reported as an unfavourable prognostic factor in various solid tumors including gastric cancer12, breast cancer13, colorectal cancer14 and NSCLC15. However, the data concerning the prognostic value of PLR in NSCLC were inconsistent. Liu et al.15 reported that elevated PLR was associated with poor prognosis in patients with NSCLC receiving chemotherapy.

Cannon et al.16 also showed that patients with high pretreatment PLR had shorter overall survival after stereotactic radiation therapy. In contrast, Pinato et al.17 failed to find the prognostic significance of PLR in primary operable NSCLC and Wu et al.18 also did not find correlation between PLR and prognosis of NSCLC. We thus collected the available publications and conducted this meta-analysis to disclose the prognostic role of PLR for overall survival (OS), disease-free survival (DFS)/progress-free survival (PFS) in NSCLC.

Results

The characteristics of included studies

The literature selection process of the eligible studies was presented in Fig. 1. A total of 11 studies15,16,17,18,19,20,21,22,23,24,25 with 3,430 patients were included in the meta-analysis. The basic characteristics of the primary studies were shown in Table 1. Of these studies, four studies15,18,20,24 were conducted in China, two studies16,23 were conducted in USA, two studies19,22 were performed in Turkey, two studies21,25 were carried out in Japan and one study17 was conducted in UK. Three studies15,18,19 included patients with advanced tumor stages, seven studies16,17,20,21,23,24,25 involved patients with early stages and one study22 included patients with all tumor stages. The articles were published from 2013 to 2015 and the NOS scores of the included studies ranged from 7–9. Five studies16,17,18,21,24 gave the definition of OS and defined OS as the length of time from treatment to day of death or last follow-up. The other six studies15,19,20,22,23,25 generally described OS as overall survival. One study24 provided the definition of DFS and defined DFS as theduration of time between the date of treatment and the date of first recurrence or last follow-up. Three studies19,20,25 generally described DFS as disease-free survival. One study18 defined PFS as the time from treatment initiation until disease progression. All the 11 studies15,16,17,18,19,20,21,22,23,24,25 investigated the prognostic value of PLR in OS and five studies18,19,20,24,25 explored the prognostic significance of PLR in DFS/PFS. The sample sizes in the included syudies ranged from 59 to 1043. Four studies18,20,21,24 were classified as large sample size (n > 300) studies and seven studies15,16,17,19,22,23,25 were small sample size (n < 300) studies. The cut-off values used by the included studies ranged from 106 to 300, the median value of which was 171, so we selected PLR = 180 to divide the cut-off values in the following subgroup analysis.

Figure 1. Flow chart of the study selection.

Figure 1

Open in a new tab

Table 1. Characteristics of all included studies.

Study Year Country Ethnicity Follow-up (month) Sample size Gender (M/F) TNM stage Cut-off Treatment methods Outcome Hazard ratio Study design NOS score
Liu15 2013 China Asian To Aug 2012 210 139/71 III–IV 152.6 Chemotherapy OS R Retrospective 8
Unal19 2013 Turkey Caucasian NA 94 88/6 II–IIIB 194 Chemoradiotherapy OS,DFS R Retrospective 8
Pinato17 2014 UK Caucasian To Sep 2012 220 110/110 I–III 300 Surgery OS R Prospective 7
Zhang20 2014 China Asian 46(1–78) 400 272/128 I–II 171 Surgery OS,DFS R Retrospective 8
Cannon16 2015 USA Caucasian 17(median) 59 31/28 I 146 Radiotherapy OS E Retrospective 7
Kawashima21 2015 Japan Asian NA 1043 671/372 I–III 300 Surgery OS R Retrospective 7
Kos22 2015 Turkey Caucasian 33(1–128) 145 130/15 I–IV 198.2 Mixed OS R Retrospective 9
Miyazaki25 2015 Japan Asian NA 97 62/35 I 118 Surgery OS,DFS E Retrospective 8
Shaverdian23 2015 USA Caucasian 28.9(median) 118 NA I–II 187.27 Radiotherapy OS E Retrospective 7
Wu18 2015 China Asian To Dec 2013 366 246/120 III–IV 119.5 Chemotherapy OS,PFS R Retrospective 7
Zhang24 2015 China Asian 43.5(1–99) 678 449/229 I–III 106 Surgery OS,DFS R Retrospective 7
Open in a new tab

NA: not available; R: reported in text; E: estimated; OS: overall survival; DFS: disease free survival; PFS: progressi on free survival; NOS: Newcastle–Ottawa Quality Assessment Scale.

PLR and OS in NSCLC

Eleven studies15,16,17,18,19,20,21,22,23,24,25 with 3,430 patients reported the data of pretreatment PLR and OS in NSCLC. Elevated PLR was associated with poor OS (HR = 1.42; 95% CI: 1.25–1.61, p < 0.001) although with heterogeneity (I2 = 63.6, Ph = 0.002; Table 2, Fig. 2).

Table 2. Summary of the meta-analysis results.

  Variable No. of studies No. of patients Effects model HR (95% CI) p Heterogeneity
I2(%) Ph
OS Overall 11 3,430 R 1.42(1.25–1.61) <0.001 63.6 0.002
Ethnicity
Asian 6 2,794 R 1.51(1.08–2.11) 0.016 76.6 0.001
Caucasian 5 636 F 1.59(1.27–1.98) <0.001 15.2 0.318
Sample size
Large 4 2,487 R 1.44(0.94–2.21) 0.098 80.8 0.001
Small 7 943 F 1.66(1.38–1.99) <0.001 7.8 0.369
Treatment
Nonsurgery 6 992 R 1.58(1.23–2.02) <0.001 50.4 0.073
Surgery 5 2,438 R 1.54(1–2.35) 0.048 73.7 0.004
Cut-off
PLR < 180 6 1,810 R 1.52(1.08–2.14) 0.017 76.1 0.001
PLR > 180 5 1,620 F 1.61(1.3–1.99) <0.001 11.8 0.339
DFS/PFS Overall 5 1,635 F 1.19(1.02–1.4) 0.027 46.8 0.111
Ethnicity
Asian 4 1,541 R 1.13(0.98–1.33) 0.165 20.8 0.285
Caucasian 1 94 − 1.8(1.15–2.81) 0.01 − −
Sample size
Large 3 1,444 F 1.12(0.94–1.34) 0.205 46.6 0.154
Small 2 191 F 1.55(1.09–2.22) 0.015 13.8 0.281
Treatment
Nonsurgery 2 460 R 1.42(0.95–2.13) 0.086 53.3 0.144
Surgery 3 1,175 F 1.11(0.91–1.34) 0.312 45.3 0.161
Open in a new tab

R: random-effects model; F: fixed-effects model; Ph: p value of Q test for heterogeneity.

Figure 2. Forest plot of the association between PLR and OS in patients with NSCLC.

Figure 2

Open in a new tab

PLR and DFS/PFS in NSCLC

There were five studies18,19,20,24,25 with 1,635 patients presenting the HR and 95% CI of PLR and DFS/PFS. The combined data showed that elevated PLR was associated with shorter DFS/PFS (HR = 1.19; 95% CI: 1.02–1.4, p = 0.027) with moderate heterogeneity (I2 = 46.8, Ph = 0.111; Table 2, Fig. 3).

Figure 3. Forest plot of the association between PLR and DFS/PFS in patients with NSCLC.

Figure 3

Open in a new tab

Subgroup analyses

To detect the potential source of heterogeneity, subgroup analyses stratified by ethnicity, sample size, treatment methods and PLR cut-off were performed. As shown in Table 2, elevated PLR did not predict poor OS in patients in large sample studies (HR = 1.44; 95% CI: 0.94–2.21, p = 0.098; I2 = 80.8, Ph = 0.001), however, elevated PLR had enhanced prognostic efficiency for poor OS in Caucasians (HR = 1.59; 95% CI: 1.27–1.98, p < 0.001; I2 = 15.2, Ph = 0.318) and when the cut-off value of PLR was more than 180 (HR = 1.61; 95% CI: 1.3–1.99, p < 0.001; I2 = 11.8, Ph = 0.339). As for the PLR in DFS/PFS, the results showed that elevated PLR did not predict poor DFS/PFS in Asians (HR = 1.12; 95% CI: 0.94–1.34, p = 0.205; I2 = 46.6 Ph = 0.154) whereas high PLR was correlated with shortened DFS/PFS in small sample studies(HR = 1.55; 95% CI: 1.09–2.22, p = 0.015; I2 = 13.8,Ph = 0.281) (Table 2).

Sensitivity analysis

Each single study was omitted every time to estimate the influence of individual data sets on the combined HR. The results showed that the pooled HRs for OS and DFS/PFS were not substantially changed (Fig. 4), indicating the robustness of our findings.

Figure 4.

Figure 4

Open in a new tab

Sensitivity analysis on the relationship between PLR and (A) OS and (B) DFS/PFS in NSCLC.

Publication bias

Begg’s test suggested no evidence of obvious publication bias (p = 0.119 for OS and p = 0.221 for DFS/PFS, respectively)(Fig. 5).

Figure 5.

Figure 5

Open in a new tab

Begg’s funnel plot of publication bias test for (A) OS and (B) DFS/PFS in NSCLC.

Discussion

In the present study, using the method of meta-analysis, we explored the prognostic impact of pretreatment PLR on OS and DFS/PFS in patients with NSCLC. By combining the HRs and 95% CIs from eleven primary studies15,16,17,18,19,20,21,22,23,24,25 with 3,430 subjects, we showed that elevated PLR was associated with poor OS (HR = 1.42; 95% CI: 1.25–1.61, p < 0.001) and poor DFS/PFS (HR = 1.19; 95% CI: 1.02–1.4, p = 0.027) in NSCLC. Furthermore, stratified analysis showed that high PLR had consistent prognostic value in NSCLC in diverse subgroup populations expect for patients included in large sample size studies (HR = 1.44; 95% CI: 0.94–2.21, p = 0.098), whereas patients with Caucasuian ethnicitic background and PLR > 180 could better predicted poor OS. The stratified analysis also showed that high PLR had no prognostic efficiency for DFS/PFS in Asian patients. All of the studies were published since 2013, highlighting the recent interest in PLR as an attractive prognostic factor. To our knowledge, this was the first meta-analysis to investigate the association between PLR and NSCLC prognostication.

Inflammation and immune responses were recognized as important stimulators for tumorigenesis since it was first proposed by Virchow26 in the 19th century. In the past several decades, a large amount of studies investigating mechanisms by which inflammation promote tumorigenesis suggested that inflammatory cells are important cross-talk factors between chronic inflammation and neoplastic growth27. Lung cancer patients often have the common feature of chronic inflammation, such as COPD27,28. In the tumor microenvironment, macrophages, neutrophils, platelets and lymphocytes produce inflammatory cytokines and chemokines, which could facilitate tumor progression29. A variety of cytokine proteins such as IL-1, IL-6 and TNF could enhance tumor cells’ capability to metastasize30. Leukocyte infiltration was also shown to be related with tumor angiogenesis31. Readily available blood based parameters including NLR, PLR and mGPS could adequately reflect the cancer-related inflammatory status and are widely investigated as prognostic factors in NSCLC32,33.

The results of this meta-analysis provided evidence supporting elevated PLR as a prognostic factor for OS in NSCLC, which was in line with a previous meta-analysis34. In addition, we noticed that in the previous work34, a variety of solid tumors were included for analysis, except for NSCLC. The previous meta-analysis34 searched literature until June 2013, but the first eligible primary study15 included in our meta-analysis was published on December 2013. Therefore, the current study first provided the statistical evidence for PLR’s prognostic role in NSCLC by meta-analysis. Interestingly, after subgroup analysis dichotomized by sample sizes of included studies, we found that high PLR no longer predicted poor OS in patients attending large sample size studies. (Table 2). However, four studies18,20,21,24 with 2,487 patients were identified as large sample studies, one21 of which recruited 1,043 subjects. This study21 may have significant impact on the results of subgroup analysis stratified by sample size, therefore, the results should be interpreted with caution. Furthermore, subgroup analysis demonstrated that patients with Caucasian ethnicitic background and a higher PLR (>180) had augmented prognostic value, because a higher PLR represented more seriously impaired immune functions in cancer patients. The prognostic role of PLR for DFS/PFS was also detected in our study whereas elevated PLR did not suggest poor DFS/PFS in Asian patients in subgroup analysis. The ethnicitic heterogenicity may account for the results. Neutrophil-to-lymphocyte ratio (NLR) was another easily available and useful index for prognosis prediction in NSCLC. Our previous work35 had demonstrated NLR might be a predicative factor of poor prognosis for NSCLC patients. In the current study, we intended to explore the prognostic role of PLR in NSCLC, which was usually compared with NLR in prognostication. We pooled coflicting data from 11 studies and showed the prognostic value of PLR for NSCLC, which extended the inflammatory prognostic factors for NSCLC.

The present study had several limitations. First, obvious heterogeneity existed in this meta-analysis. Although sensitivity analysis and publication bias test indicated the credibility of the results, we could not rule out that different study criteria used in the primary resulted in the discrepancies between studies. Second, the nonuniform cutoff value defining elevated PLR may not be applicable for clinical use, an identical cutoff value was needed. Finally, the summary HR and 95% CI rather than individual patient data were used for calculation of pooled HR and 95% CI in this meta-analysis.

In conclusion, our study for the first demonstrated the prognostic role of elevated PLR for poor OS and DFS/PFS in NSCLC by meta-analysis. Considering the limitations of our study, further well-designed studies using uniform PLR cutoff value are warranted to test our results.

Methods

Search strategy and eligibility criteria

The databases of Web of Science, Embase and Pubmed were thoroughly searched until December, 2015. The following terms were used in separation or in combination: “PLR”, “platelet-lymphocyte ratio”, “platelet to lymphocyte ratio”, “lung cancer”, “lung carcinoma” or “NSCLC”. Reviews and reference lists were also manually retrieved for additional publications. The publication language was limited to English.

The inclusion criteria were: 1) patients pathologically diagnosed as NSCLC; 2) PLR was measured by blood-based methods before formal treatment; 3) HRs and 95% CIs for PLR in OS and (or) DFS/PFS were reported in text or sufficient data was provided for the calculation of HRs and 95% CIs. 4) full text papers published in English.

The exclusion criteria were as follows: 1) review, meeting abstract, letter, not full text in English; 2) duplicate data; 3) nonhuman studies; 4) did not present the cut-off value for elevated PLR.

Data extraction

Two independent reviewers (XB,G and XS,G) extracted the following information from the eligible studies: the surname of the first author, year of publication, study country, sample size, treatment methods, cut-off value of high PLR and survival data. Disagreements were resolved by joint discussion.

Quality assessment

The quality assessment of primary studies was performed according to Newcastle-Ottawa quality assessment Scale (NOS)(http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). This scale is composed of three parts: selection, comparability and outcome assessment. The full mark is 9 points and studies labeled with ≥6 points were regarded as high-quality researches.

Statistical analysis

The hazard ratio (HR) with 95% confidence intervals(95% CI) were directly obtained from the articles or estimated according to the methods reported by Tierney et al.36. Heterogeneity among primary studies was evaluated using the Cochran Q test and I2 statistic. Cochran Q test’p value < 0.10 or I2 > 50% indicated large heterogeneity between studies and random effects models (DerSimonian Laird method) was used to calculate the pooled HR and 95% CI. Otherwise, the fixed effects model (Mantel-Haenszel method) was used. Studies with sample size >200 were considered as large sample studies, otherwise was regarded as small sample size. Subgroup analyses stratified by ethnicity, sample size, treatment methods and PLR cut-off were carried out.

Sensitivity analysis was conducted by omitting each single study and recalculating their HRs. Publication bias was evaluated using Begg’s test37. All statistical analyses were performed using Stata 12(Stata Corp., College Station, Texas). P < 0.05 was considered statistically significant.

Additional Information

How to cite this article: Gu, X. et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci. Rep. 6, 23893; doi: 10.1038/srep23893 (2016).

Acknowledgments

This work was supported by a grant from the Clinical Features Research of Capital (No. Z141107002514160).

Footnotes

Author Contributions M.W.M., S.B.Q., W.X. and X.B.G. conceived and designed this study; X.B.G., X.-S.G. and X.Q. searched databases and collected the data; X.B.L., S.Q.S., D.Z. and W.W. performed the statistical analysis, interpretation of data; X.B.G., X.S.G., W.X. and H.Y. wrote the manuscript. All authors reviewed the final manuscript.

References

  1. Torre L. A. et al. Global Cancer Statistics, 2012. CA-Cancer J. Clin. 65, 87–108, 10.3322/caac.21262 (2015). [DOI] [PubMed] [Google Scholar]
  2. Shepherd F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132, 10.1056/NEJMoa050753 (2005). [DOI] [PubMed] [Google Scholar]
  3. Solomon B. J. et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N. Engl. J. Med. 371, 2167–2177, 10.1056/NEJMoa1408440 (2014). [DOI] [PubMed] [Google Scholar]
  4. Heist R. S. & Engelman J. A. SnapShot: non-small cell lung cancer. Cancer Cell 21, 448.e442, 10.1016/j.ccr.2012.03.007 (2012). [DOI] [PubMed] [Google Scholar]
  5. Ettinger D. S. et al. Non-Small Cell Lung Cancer, Version 1.2015. J. Natl. Compr. Cancer Netw. 12, 1738–1761 (2014). [DOI] [PubMed] [Google Scholar]
  6. Rosell R., Bivona T. G. & Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382, 720–731 (2013). [DOI] [PubMed] [Google Scholar]
  7. Molina J. R., Yang P. G., Cassivi S. D., Schild S. E. & Adjei A. A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83, 584–594 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hanahan D. & Weinberg R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, 10.1016/j.cell.2011.02.013 (2011). [DOI] [PubMed] [Google Scholar]
  9. Grivennikov S. I., Greten F. R. & Karin M. Immunity, Inflammation, and Cancer. Cell 140, 883–899, 10.1016/j.cell.2010.01.025 (2010). [DOI] [PMC free article] [PubMed]
  10. Kim I. Y., You S. H. & Kim Y. W. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg. 14, 7, 10.1186/1471-2482-14-94 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stotz M. et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer Br. J. Cancer 109, 2026–2026, 10.1038/bjc.2013.591 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Aliustaoglu M. et al. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 27, 1060–1065, 10.1007/s12032-009-9335-4 (2010). [DOI] [PubMed] [Google Scholar]
  13. Azab B. et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30, 432, 10.1007/s12032-012-0432-4 (2013). [DOI] [PubMed] [Google Scholar]
  14. He W. et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30, 439, 10.1007/s12032-012-0439-x (2013). [DOI] [PubMed] [Google Scholar]
  15. Liu H. et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis 5, 783–789 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cannon N. A. et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J. Thorac. Oncol. 10, 280–285 (2015). [DOI] [PubMed] [Google Scholar]
  17. Pinato D. J. et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br. J. Cancer 110, 1930–1935, 10.1038/bjc.2014.145 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wu G. et al. Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients. Thorac Cancer. 6, 275–287 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Unal D., Eroglu C., Kurtul N., Oguz A. & Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev 14, 5237–5242 (2013). [DOI] [PubMed] [Google Scholar]
  20. Zhang T. et al. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PloS one 9, e111494, 10.1371/journal.pone.0111494 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kawashima M. et al. Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg 21, 637–643, 10.1093/icvts/ivv223 (2015). [DOI] [PubMed] [Google Scholar]
  22. Kos M. et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. Wien Klin Wochenschr. 10.1007/s00508-015-0724-8 (2015). [DOI] [PubMed] [Google Scholar]
  23. Shaverdian N. et al. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Clin Lung Cancer. 10.1016/j.cllc.2015.07.007. (2015). [DOI] [PubMed] [Google Scholar]
  24. Zhang H. et al. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 210, 526–535, 10.1016/j.amjsurg.2015.03.022 (2015). [DOI] [PubMed] [Google Scholar]
  25. Miyazaki T. et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 47, e140–e145 (2015). [DOI] [PubMed] [Google Scholar]
  26. Mantovani A., Allavena P., Sica A. & Balkwill F. Cancer-related inflammation. Nature 454, 436–444, 10.1038/nature07205 (2008). [DOI] [PubMed] [Google Scholar]
  27. Houghton A. M. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13, 233–245, 10.1038/nrc3477 (2013). [DOI] [PubMed] [Google Scholar]
  28. Coussens L. M. & Werb Z. Inflammation and cancer. Nature 420, 860–867, 10.1038/nature01322 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361–371, 10.1038/nrc2628 (2009). [DOI] [PubMed] [Google Scholar]
  30. Hanahan D. & Weinberg R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646–674, 10.1016/j.cell.2011.02.013 (2011). [DOI] [PubMed] [Google Scholar]
  31. Esposito I. et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57, 630–636 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Cannon N. A. et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90, S621 (2014). [DOI] [PubMed] [Google Scholar]
  33. Pahoff C., Singh M. & Sriram K. Prognostic utility of platelet lymphocyte ratio in patients with stage IV NSCLC. Respirology 20, 150 (2015). [Google Scholar]
  34. Templeton A. J. et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 23, 1204–1212, 10.1158/1055-9965.epi-14-0146 (2014). [DOI] [PubMed] [Google Scholar]
  35. Gu X. B., Tian T., Tian X. J. & Zhang X. J. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 5, 12493, 10.1038/srep12493 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tierney J. F., Stewart L. A., Ghersi D., Burdett S. & Sydes M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16, 10.1186/1745-6215-8-16 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Begg C. B. & Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994). [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES